Angiogenesis and apoptosis in glioma: two arenas for promising new therapies.
New therapies for gliomas are urgently needed in view of the very marginal increase in patient survival that has been achieved over the past two decades, which is only somewhat mitigated by improvements in quality of life. Two relatively recent fields of research that hold out great promise in this area, are angiogenesis and apoptosis. Depriving growing tumors of the blood supply they need, or tipping the balance in the cancer cell towards cell death, both provide conceptually elegant approaches to therapy, with the hope of great efficacy and little toxicity. However, attempts at successfully translating exciting laboratory findings to the clinic have been slowed by the complexity of the underlying biology. In this article we examine some of the issues that have impeded progress, and examine the potential role that integrins may play as targets, with a role in both angiogenesis and apoptosis.
Bögler
Oliver
O
William and Karen Davidson Laboratory of Brain Tumor Biology, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, Michigan 48202, USA. obogler@mdanderson.org
Mikkelsen
Tom
T
D000818:Animals; D017209:Apoptosis / Q000502:physiology*; D005910:Glioma / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism
D053221:TNF-Related Apoptosis-Inducing Ligand